Consensus BioCryst Pharmaceuticals, Inc.

Stocks

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-12 EDT			5-day change	1st Jan Change
8.700 ^USD	+2.35%		+3.45%	+11.54%

06-12	BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment	MT
06-12	BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting	CI

Evolution of the Average Target: BioCryst Pharmaceuticals, Inc.

Evolution of the Target Price: BioCryst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: BioCryst Pharmaceuticals, Inc.

2707e378.J6w336wJy_xb7y6RwdomgxECpZX9jaRT47yX1ARMi6c.b95lm-1B-rgUiX7d8qxP23NqlqWJyOEYlOzApD0ixMVonQ-zxTCNiQytaw~6bfa17cf50eb64a553379c2d6eeff50d

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

04-07	RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating	MT
03-25	BioCryst Shares Remain Undervalued, RBC Says	MT
02-27	Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating	MT
01-30	RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating	MT
01-08	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
12-30	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
25-10-15	RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating	MT
25-10-08	RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating	MT
25-10-01	Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12	MT
25-06-30	Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating	MT
25-05-06	RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	MT
25-02-25	RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	MT
24-05-07	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT
23-09-18	BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	MT
23-08-04	Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	MT
23-08-04	RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	MT
23-07-13	BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	MT
23-07-07	RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	MT
23-04-20	Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	MT
23-04-06	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $9 From $10, Maintains Sector Perform - Speculative Risk Rating	MT
23-02-22	Needham Upgrades BioCryst Pharmaceuticals to Buy From Hold With $14 Price Target	MT
23-02-22	RBC Adjusts Price Target on BioCryst Pharmaceuticals to $10 From $12, Maintains Sector Perform Rating	MT
22-11-02	Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Price Target	MT
22-11-02	RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, Keeps Sector Perform Rating, Speculative Risk Qualifier	MT
22-08-05	Oppenheimer Downgrades BioCryst Pharmaceuticals to Perform From Outperform, Removes $13 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOCRYST PHARMACEUTICALS, INC.					+144.83%
	ARGENX SE					+8.05%
	WUXI APPTEC CO., LTD.					+46.39%
	BIONTECH SE					+36.71%
	INSMED INCORPORATED					+101.96%
	WUXI BIOLOGICS (CAYMAN) INC.					+50.93%
	GENMAB A/S					+42.87%
	EXELIXIS, INC.					-7.77%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+31.9%
	PHARMAESSENTIA CORPORATION					-14.59%
	Average					+44.13%
	Weighted average by Cap.					+34.58%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.700USD

Average target price

21.30USD

Spread / Average Target

+144.83%

High Price Target

32.00USD

Spread / Highest target

+267.82%

Low Price Target

13.00USD

Spread / Lowest Target

+49.43%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Wedbush
Evercore ISI
JMP Securities
Jefferies & Co.
BofA Securities
Needham & Co.
Barclays
Oppenheimer
Piper Sandler
JPMorgan Chase
Cantor Fitzgerald
HC Wainwright
Cowen